Please provide your email address to receive an email when new articles are posted on . Older, fit patients with acute myeloid leukemia who received decitabine had transplant and survival rates ...

The DNA promoter methylation inhibitor decitabine exhibited some antitumor properties in tests of adrenocortical carcinoma cells. The drug’s activity in recovering gene expression suggests that ...

Venetoclax and decitabine in treating participants with relapsed/refractory acute myeloid leukemia or relapsed high-risk myelodysplastic syndrome. ClinicalTrials.gov. Updated January 5, 2024.

April 20, 2010 — The hypomethylating agents azacitidine (Vidaza, Pharmion) and decitabine (Dacogen, MGI Pharma) are an "important addition" to the therapeutic armamentarium for myelodysplastic ...

Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial On the basis of encouraging results with decitabine + ATRA in almost 100 ...

Adding venetoclax to oral decitabine-cedazuridine improves responses in higher-risk MDS and CMML patients. Inqovi, an oral decitabine-cedazuridine combination, was FDA approved in 2020 for primary ...

Drug Name : Decitabine This medication is a nucleoside analog, prescribed for myelodysplastic syndromes (MDS). More info about Decitabine Brand Names or Trade Names of Decitabine ...

INQOVI (decitabine and cedazuridine) tablets, for oral use, is approved for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, ...

Novel combination of decitabine, venetoclax, and ponatinib achieved bone marrow remission in 80% of patients with untreated chronic myeloid leukemia (CML) and Philadelphia chromosome-positive ...

Of these patients, 32 had MDS with excess blasts, six had CMML, and one had atypical CMML. In the phase I portion of the trial, treatment consisted of oral decitabine 35 mg plus cedazuridine 100 ...